Pre-made Tidutamab benchmark antibody ( Bispecific Mixed mAb and scFv, anti-SSTR2;CD3E therapeutic antibody, Anti-T3E/TCRE/IMD18/CD3epsilon Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Tidutamab biosimilar, Bispecific Mixed mAb and scFv, Anti-SSTR2;CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Tidutamab (formerly XmAb 18087) is a humanised, Fc domain-containing, bispecific monoclonal antibody targeting somatostatin receptor 2 (SSTR2) and a cytotoxic T-cell binding domain (CD3), being developed by Xencor, for the treatment of neuroendocrine tumours (NET) and gastrointestinal stromal tumours (GIST).

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-570-1mg	1mg	Inquiry
GMP-Bios-ab-570-10mg	10mg	Inquiry
GMP-Bios-ab-570-100mg	100mg	Inquiry
GMP-Bios-ab-570-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Tidutamab biosimilar, Bispecific Mixed mAb and scFv, Anti-SSTR2;CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody
INN Name	Tidutamab
Target	SSTR2;CD3E
Format	Bispecific Mixed mAb and scFv
Derivation	Bispecific antibody
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa;Lambda
Highest_Clin_Trial (Jan '20)	Phase-I
Est. Status	Discontinued
100% SI Structure	None;None
99% SI Structure	None;None
95-98% SI Structure	None;None
Year Proposed	2018
Year Recommended	2019
Companies	ICON;Xencor
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Gastrointestinal stromal tumours;Neuroendocrine tumours
Development Tech	na